Crane Co. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Crane Co. on July 22, 2013. The filing primarily addresses the announcement of results of operations for the quarter ended June 30, 2013 (Item 2.02) and provides a detailed update on asbestos liability claims and costs (Item 8.01). The company is incorporated in Delaware and maintains its principal executive offices in Stamford, CT.
Key Financial Metrics: Asbestos Liability and Cash Flow
The filing does not provide consolidated revenue, profit, or general liquidity metrics for the quarter; these are referenced in attached Exhibits 99.1 and 99.2. However, specific financial data regarding asbestos litigation is provided:
- Asbestos Liability Reserve: $749 million as of June 30, 2013 (down from $894 million as of December 31, 2011).
- Current Portion of Liability: $92 million, representing estimated costs to be paid within the next twelve months.
- Insurance Receivable Asset: $188 million as of June 30, 2013 (down from $225 million as of December 31, 2011).
- Costs Incurred (Six Months Ended June 30, 2013): $43.1 million total (Settlement/Indemnity: $14.3 million; Defense: $28.9 million).
- Pre-tax Cash Payments (Six Months Ended June 30, 2013): $28.9 million net of insurance receipts.
- Insurance Coverage: Approximately 25% of the estimated liability is expected to be reimbursed by insurers.
Material Changes and Claim Activity
Asbestos claim activity for the three and six months ended June 30, 2013, showed the following trends compared to prior periods:
- Pending Claims: Decreased to 54,969 as of June 30, 2013, from 57,559 in the prior year period.
- New Claims: 734 new claims filed in the quarter (down from 894 in the prior year quarter).
- Dismissals: 1,756 claims dismissed in the quarter (up significantly from 474 in the prior year quarter).
- Settlements: 217 claims settled in the quarter (down from 258 in the prior year quarter).
- Cost Trends: Total costs incurred for the six months ended June 30, 2013 ($43.1 million) decreased compared to the same period in 2012 ($49.7 million). Net cash payments also decreased to $28.9 million from $39.2 million in the prior year period.
Outlook, Risks, and Unusual Items
Liability Estimate Stability: Management determined that no change to the asbestos liability estimate was warranted for the period ended June 30, 2013. The estimate covers claims filed or projected through 2021. The company believes the outlook for mesothelioma claims (which drive ~90% of costs) is reasonably stable due to favorable case law trends and legislative restrictions in key jurisdictions.
Significant Litigation Updates:
- Ivo Peraica Claim (NY): A $35 million verdict was entered on March 1, 2013. Plaintiffs requested judgment of $19.3 million. The company is appealing and argues damages are excessive.
- Ronald Dummitt Claim (NY): A judgment of $4.9 million was entered after a reduction from a $32 million verdict. The company has appealed.
- James Hellam Claim (CA): A judgment of $1.282 million was entered. The company is pursuing post-trial motions and appeals.
- William Paulus Claim (CA): A judgment of $0.8 million was entered. The company has appealed.
Risks and Uncertainties: The company notes significant uncertainty regarding future claims, settlement costs, and insurance recoveries. Factors such as new mesothelioma filings, average settlement costs, dismissal rates, and defense costs are interdependent. While the company expects to incur additional charges beyond current reserves, it cannot reasonably estimate amounts beyond 2021.
Investor Verification Checklist
- Verify the full quarterly financial results (Revenue, Net Income, EPS) in the attached Earnings Press Release (Exhibit 99.1) and Financial Data Supplement (Exhibit 99.2), as they are not detailed in the 8-K text.
- Monitor the status of the Ivo Peraica and Ronald Dummitt appeals, as these represent significant potential liabilities.
- Review the "coverage-in-place" agreements with excess insurers to understand the stability of the 25% reimbursement rate.
- Track the number of new mesothelioma claims filed, as this is the primary driver of the liability estimate.
- Assess the impact of the $92 million current portion of the asbestos liability on near-term cash flow projections.